**AIFA specifications on Covid-19 coronavirus disease and use of ACE-Inhibitors and Sartans**

URL:<https://www.aifa.gov.it/web/guest/-/precisazioni-aifa-su-malattia-da-coronavirus-covid-19-ed-utilizzo-di-ace-inibitori-e-sartani>

[Translated] Text:

The Italian Medicines Agency, regarding the alleged effect of therapies based on anti-hypertensive medicines belonging to the class of angiotensin converting enzyme inhibitors (ACE inhibitors), or angiotensin II receptor antagonists ( sartani), on the transmission and evolution of coronavirus disease (Covid-19), intends to clarify that to date there is no scientific evidence regarding clinical or epidemiological studies, but only molecular hypotheses verified with in vitro studies. Therefore, based on current knowledge, it is considered appropriate to recommend not to modify the therapy in progress with anti-hypertensives (whatever the therapeutic class) in well-controlled hypertensive patients, as they expose frail patients to potential new side effects or an increase in risk of cardiovascular adverse events does not appear justified.

For the same reasons, compared to the hypothesis of using ACE inhibitors and sartans also in healthy people for prophylactic purposes, it should be remembered that these drugs should be used exclusively for the treatment of pathologies for which there is an approved and described indication in the Summary of Product Characteristics and Package Leaflet.

Similar positions have been taken by the Italian Society of Arterial Hypertension [1], by the Italian Society of General Medicine and Primary Care [2], by the European Society of Cardiology [3] and by the Italian Society of Pharmacology [4].

Citations:

* [1] https://siia.it/notizie-siia/farmaci-antiipertensivi-e-rischio-di-covid-19-il-comunicato-della-siia/
* [2] https://www.simg.it/supporto-e-condivisione-della-posizione-della-siia-sulluso-degli-ace-inibitori-nella-presente-situazione-epidemica/
* [3] https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang
* [4] https://www.sifweb.org/documenti/document\_2020-03-13\_documento-informativo-della-societa-italiana-di-farmacologia-uso-di-ace-inibitori-sartani-ed-infezione-da-covid-19